Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Preps Eritoran Phase III Sepsis Trial Based On Phase II Cut In Mortality

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Eisai will commence a Phase III study of eritoran (E5564) for severe sepsis by the first quarter of 2006 after a Phase II trial showed a 6.4% mortality reduction versus placebo at 28 days, the firm said Aug. 29
Advertisement

Related Content

Licensing In Brief
Licensing In Brief
Lilly’s Search For Sepsis Biomarkers Could Provide Early Signal For Xigris Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS003032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel